Two pathways. One serious shift in how your body handles food.
Why pay 6x more for fewer answers?
Both are weekly injectable GLP-1 medications. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both GLP-1 and GIP. In head-to-head trials, tirzepatide produced greater average weight loss. Some patients also report fewer GI side effects at higher doses. Your provider will recommend which is right for you.
In a 72-week clinical trial of adults with obesity, the highest dose of tirzepatide produced an average weight loss of ~21% body weight. Results in real-world settings vary depending on starting weight, dose, lifestyle, and how your body responds.
No. Obu is cash-pay. Pricing is transparent, the same at every dose, and there are no hidden membership fees. We accept HSA/FSA and Buy Now, Pay Later through Klarna, Afterpay, and Affirm.
Most side effects are mild and improve over the first few weeks: nausea, stomach upset, constipation or diarrhea, fatigue, and headaches. Serious side effects are uncommon. Your provider will work with you on dose timing and adjustments.
No. Compounded medications are not FDA-approved. They are prepared by U.S.-licensed pharmacies under Section 503A and dispensed only with a patient-specific prescription. Brand-name tirzepatide products such as Mounjaro® and Zepbound® are FDA-approved and not compounded.
Yes — anytime from your patient portal. Cancellation doesn't affect orders already shipped from the pharmacy.
